Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 21 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-11.48 Insider Own27.04% Shs Outstand23.41M Perf Week-0.39%
Market Cap178.62M Forward P/E- EPS next Y-2.40 Insider Trans1.03% Shs Float17.08M Perf Month-3.05%
Income-159.13M PEG- EPS next Q-1.03 Inst Own32.35% Short Float9.74% Perf Quarter8.38%
Sales0.00M P/S- EPS this Y-29.84% Inst Trans-24.26% Short Ratio2.47 Perf Half Y-7.78%
Book/sh-6.10 P/B- EPS next Y61.52% ROA-281.52% Short Interest1.66M Perf Year-78.20%
Cash/sh2.02 P/C3.78 EPS next 5Y- ROE-827.71% 52W Range4.00 - 37.00 Perf YTD-3.17%
Dividend Est.- P/FCF- EPS past 5Y52.49% ROI- 52W High-79.38% Beta0.72
Dividend TTM- Quick Ratio1.07 Sales past 5Y12.77% Gross Margin- 52W Low90.56% ATR (14)0.52
Dividend Ex-Date- Current Ratio1.07 EPS Y/Y TTM-128.91% Oper. Margin0.00% RSI (14)51.33 Volatility6.46% 7.01%
Employees24 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.14 Target Price37.43
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q-1444.33% Payout- Rel Volume1.22 Prev Close7.59
Sales Surprise- EPS Surprise-70.35% Sales Q/Q- EarningsMay 16 BMO Avg Volume673.58K Price7.63
SMA203.24% SMA50-3.42% SMA200-2.81% Trades Volume821,448 Change0.53%
Date Action Analyst Rating Change Price Target Change
Mar-27-24Upgrade BTIG Research Neutral → Buy $50
Feb-15-24Upgrade Chardan Capital Markets Neutral → Buy $3
Jan-25-24Upgrade Guggenheim Neutral → Buy
Dec-27-23Upgrade CapitalOne Equal Weight → Overweight $5
Aug-31-23Downgrade H.C. Wainwright Buy → Neutral $5 → $1
Aug-31-23Downgrade Chardan Capital Markets Buy → Neutral
Aug-30-23Downgrade Guggenheim Buy → Neutral
Aug-30-23Downgrade CapitalOne Overweight → Equal Weight
Aug-30-23Downgrade Cantor Fitzgerald Overweight → Neutral $4.50 → $1
Aug-30-23Downgrade BTIG Research Buy → Neutral
Jun-17-24 08:00AM
Jun-12-24 10:00AM
Jun-11-24 09:05AM
Jun-10-24 08:00AM
Jun-06-24 10:30AM
08:05AM Loading…
May-28-24 08:05AM
May-17-24 04:27AM
May-15-24 10:53PM
May-13-24 11:18AM
May-09-24 08:45AM
May-02-24 09:05AM
Apr-29-24 09:00AM
Apr-26-24 06:37AM
04:15PM Loading…
Apr-15-24 04:15PM
Apr-10-24 03:30PM
Mar-22-24 07:35AM
Mar-18-24 05:10PM
Mar-12-24 08:05AM
Mar-06-24 03:36PM
Feb-25-24 01:37PM
Feb-14-24 05:27PM
Jan-31-24 08:05AM
Jan-24-24 08:06AM
Jan-23-24 08:00AM
Jan-02-24 10:18PM
Dec-27-23 02:03PM
09:30AM Loading…
Dec-26-23 02:15PM
Dec-22-23 08:05AM
Dec-19-23 08:05AM
Dec-06-23 08:05AM
Nov-27-23 08:05AM
Nov-15-23 02:04PM
Nov-14-23 08:05AM
Nov-09-23 08:52AM
Nov-02-23 08:05AM
Nov-01-23 08:05AM
Oct-17-23 05:22PM
Oct-11-23 05:49PM
Sep-29-23 08:05AM
Sep-21-23 08:05AM
Sep-05-23 08:05AM
Aug-31-23 10:15AM
Aug-30-23 06:11AM
Aug-28-23 11:47AM
Aug-14-23 09:55AM
Aug-01-23 08:45AM
Jun-11-23 08:45AM
Jun-06-23 01:59PM
May-15-23 08:05AM
Apr-27-23 08:05AM
Apr-10-23 11:43AM
Mar-13-23 07:00AM
Feb-14-23 08:05AM
Feb-07-23 08:05AM
Jan-19-23 08:05AM
Jan-11-23 01:00PM
Jan-09-23 08:05AM
Jan-02-23 07:31AM
Dec-29-22 09:05AM
Dec-23-22 09:00AM
Dec-22-22 08:05AM
Dec-01-22 08:05AM
Nov-22-22 08:05AM
Nov-01-22 09:55AM
Oct-28-22 08:05AM
Oct-05-22 06:09AM
Sep-27-22 08:05AM
Sep-26-22 08:35AM
Sep-07-22 08:05AM
Aug-30-22 09:39AM
Aug-15-22 08:05AM
Aug-10-22 08:05AM
Aug-04-22 08:05AM
Jul-26-22 07:18AM
Jul-05-22 08:05AM
Jun-14-22 08:05AM
May-31-22 08:05AM
May-27-22 07:25AM
May-18-22 08:05AM
May-13-22 08:05AM
May-10-22 08:35AM
May-09-22 08:35AM
May-04-22 12:02PM
Apr-22-22 08:05AM
Apr-05-22 08:05AM
Apr-04-22 07:45PM
Mar-31-22 08:05AM
Mar-03-22 08:05AM
Feb-24-22 08:05AM
Feb-16-22 10:59AM
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Haddadin Yezan MuntherDirectorMar 28 '24Buy11.821,88222,2425,049Mar 29 10:39 AM
Evanson JeffCHIEF COMMERCIAL OFFICERMar 07 '24Buy0.4262,48426,243808,459Mar 11 04:43 PM